Econostrum | Economic News in the Mediterranean
en.econostrum


   
en.econostrum



           

France's EA Pharma to acquire Spanish group Drasanvi




France's EA Pharma to acquire Spanish group Drasanvi
FRANCE / SPAIN. The pharmaceutical group EA Pharma officially announced on Wednesday 20 October 2021 that it "has entered into exclusive negotiations with Drasanvi, with a view to acquiring a majority stake in the Spanish group."

"These two entities share a common culture: that of developing differentiating and high-quality products," comments Thierry Verne, CEO of EA Pharma in a statement. For his counterpart Oscar Lopez, founder of Drasanvi, who will remain in his position, "this merger is a great step forward in its international expansion, we will strengthen both companies, innovation and commitment to quality will continue to be our trademarks."

Founded twenty-five years ago and headquartered in Villadangos del Páramo (province of Castilla y León in the north of the country), the family-owned group Drasanvi (€15m turnover and 200 employees) specialises in food supplements, natural cosmetics and health nutrition with a thousand references. It markets the brands Super Alimentos, Collmar, Botanical Bio, Immunol and Oseogen and Vital pur. Drasanvi has three production facilities in Spain and seven subsidiaries (Portugal, Lebanon, Costa Rica, Chile, Mexico, Peru and China) for its international activities, which began in 2014 with the creation of an export department. The company also works with France, Albania, Russia and the UK.

Fourth acquisition in five years

Claiming to have been founded in 1948, when Laboratoire des Granions was established in Monaco, EA Pharma was formed in the 2000s through the merger of the aforementioned Monegasque company, Paris-based Laboratoire Merle and Mougin-based Equilibre Attitude.
The company, based in Sophia-Antipolis (Mougins - Alpes-Maritimes) and owned by the Parisian investment fund Motion Equity Partners, develops a range of oligotherapy medicines, food supplements, cosmetics and sports nutrition products under the brand names Granions, Chondrosteo, Eafit, Foucaud, Punchpower, Conceptio, Duab, Oligostim and Oligosol. It has a production site dedicated to oligotherapy in Monaco.

With a turnover of €52m in 2021 and 150 employees, the French company is therefore continuing its external growth, with its first international operation after the successive acquisitions in France of Laboratoire Nutrivercell (Duab brand) in 2017, Oligostim in 2019 and Labcatal (Oligosol, Rubozinc and Lithioderm brands) in 2020.

EA Pharma's acquisition of Drasanvi, which is part of its European expansion strategy, is expected to be completed in the last quarter of 2021.

Eric Apim


Thursday, October 21st 2021



Article read 361 times


Articles which should interest to you
< >

Thursday, November 25th 2021 - 16:45 Morocco signs a security cooperation agreement with Israel